NK Cell Stimulation (via JadiCell)
Various Cancers
Key Facts
About Therapeutic Solutions International
Therapeutic Solutions International is a publicly traded biotech holding company (TSOI) with a mission to develop novel immunotherapies and regenerative medicines. Its core achievement lies in establishing a diversified portfolio of early-stage assets, primarily focused on natural killer (NK) cells and mesenchymal stem cells (MSCs), targeting cancer, neurological trauma, and inflammatory conditions. The company's strategy revolves around a capital-efficient holding structure, in-licensing promising science, and advancing programs through subsidiary entities to attract partnership capital. However, its progress is characterized by early, pre-clinical, and Phase I assets, with limited late-stage clinical validation and no commercial revenue to date.
View full company profileTherapeutic Areas
Other Various Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Oncology/Immuno-oncology Portfolio | MSD | Phase III/Commercial |
| Bevacizumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| LADR Platform | LadRx | Preclinical |
| Zip-Code Library for Oncology | Kodikaz Therapeutic Solutions | Pre-clinical |
| Proprietary RLT Pipeline | Affibody | Not Specified (Preclinical-Phase 2) |
| Preclinical ASO Portfolio | Isarna Therapeutics | Preclinical |
| SPACE-GM Microenvironment Analysis | Enable Medicine | Research |
| Oncology Program(s) | CIS Pharma | Pre-clinical |
| Max Access Solutions (with The Max Foundation) | Tanner Pharma Group | N/A (Donation/Distribution Program) |
| CPA Platform in Oncology | InnoSIGN | Development |
| Oncology Services | Transcure Bioservices | Preclinical |
| SBX 2021 | Stramsen Biotech | Early-stage Clinical |